Open Label Study of Subcutaneous Homoharringtonine in Patients with Advanced CML Study Type: Interventional

Article

This study will be evaluating the efficacy of subcutaneous homoharringtonine (CGX-635) in the treatment of patients with CML who have failed or are intolerant to tyrosine kinase inhibitor therapy.

Age/Sex Requirements: 18 years+

Sponsor: ChemGenex Pharmaceuticals

Purpose: This study will be evaluating the efficacy of subcutaneous homoharringtonine (CGX-635) in the treatment of patients with CML who have failed or are intolerant to tyrosine kinase inhibitor therapy. The focus of the study will be clinical response, with secondary measures including the degree of hematologic response, time to response, time to progression, and patient survival rate.

Click here to access this third-party website.

Related Videos
Katie Ross-Driscoll, PhD, MPH | Credit: Regenstrief Institute
Video 3 -  4 KOLs are featured in, "Collaborating with Specialists: Primary Care Clinician’s Evolving Role in HE Management"
Video 3 -  4 KOLs are featured in, "HE Experts on Symptoms, Risk Factors, Diagnosis Challenges, and Severity Grading"
Shauna Applin, ARNP, an expert on HIV
© 2024 MJH Life Sciences

All rights reserved.